Horizon Pharma Inc (HZNP) 20.53 $HZNP Horizon Pharma

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Horizon Pharma Inc (HZNP) 20.53 $HZNP

Horizon Pharma raises outlook
at Investor's Business Daily - Fri Feb 27, 5:53PM CST
The specialty drugmaker's Q4 EPS was 27 cents, up from a loss a year ago and beating views by 5 cents. Revenue more than tripled to $103.8 mil, above views, on drug acquisitions. Older drug sales also rose in Q4. Horizon Pharma (HZNP) raised '15...
HZNP: 20.53 (+1.46)

J.C. Penney and Gap are big market movers
AP - Fri Feb 27, 3:55PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
MNST: 141.12 (+16.38), HZNP: 20.53 (+1.46), CLNE: 6.01 (+0.97)

Stocks Drop In Final Hour, But Volume Remains Tame
at Investor's Business Daily - Fri Feb 27, 3:22PM CST
Stocks settled lower in the final hour of trading to finish the session down, although the indexes finished February with strong gains. The Nasdaq closed lower by 0.5%, the S&P 500 fell 0.3% and the Dow Jones industrial average dropped 0.4%. Volume...
MNST: 141.12 (+16.38), ARUN: 24.81 (+2.20), HZNP: 20.53 (+1.46), CRI: 88.77 (+1.46), HPQ: 34.84 (+0.83), AMWD: 52.66 (+3.60)

3 Stocks Driving The Health Care Sector Higher
at The Street - Fri Feb 27, 11:12AM CST
TheStreet highlights 3 stocks pushing the health care sector higher today.
NVO: 47.75 (+0.22), BAX: 69.15 (+0.48), HZNP: 20.53 (+1.46)

Horizon Pharma's (HZNP) CEO Timothy Walbert on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Feb 27, 11:01AM CST

HZNP: 20.53 (+1.46)

Horizon Pharma Soars On Q4 Beat, Guidance Raise
at Investor's Business Daily - Fri Feb 27, 10:48AM CST
Specialty drugmaker Horizon Pharma (HZNP) beat analysts' Q4 expectations and raised its 2015 guidance Friday, sending its stock up 10% to a new high. Horizon's revenue in the quarter more than tripled to $103.8 million, about $8 million above...
ESRX: 84.79 (+0.25), AZN: 68.90 (-0.11), HZNP: 20.53 (+1.46), CVS: 103.87 (-0.30)

Horizon Pharma (HZNP) Stock Spikes Today on Raised Guidance Despite Quarterly Earnings Loss
at The Street - Fri Feb 27, 9:31AM CST
Horizon Pharma (HZNP) shares are up almost double digits following the company's earnings beat and revised fiscal 2015 guidance.
HZNP: 20.53 (+1.46)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 8:15AM CST

MNST: 141.12 (+16.38), SREV: 3.72 (+0.24), OCN: 8.14 (-1.64), ARUN: 24.81 (+2.20), CVSL: 2.55 (-1.85), NBG: 1.57 (-0.16), CLNE: 6.01 (+0.97), RESN: 10.40 (-5.07), ATOS: 1.92 (-0.07), CYCC: 1.50 (+0.41), NVAX: 9.15 (-0.16), CYTX: 1.12 (-0.01), TUBE: 13.82 (-4.12), HZNP: 20.53 (+1.46), PBPB: 13.44 (-1.25), SD: 1.77 (-0.12), FRO: 2.51 (-0.27), TBIO: 1.74 (-0.47), BLOX: 23.25 (+2.02), DRL: 0.72 (-0.62), GENE: 5.83 (-0.71), MOSY: 1.80 (-0.22), XIN: 3.06 (+0.55), JCP: 8.50 (-0.62), MEET: 1.94 (unch), VIMC: 9.48 (+0.67), SPLK: 67.25 (-2.32), WTW: 11.33 (-6.23)

Horizon Pharma (HZNP) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Fri Feb 27, 6:55AM CST

HZNP: 20.53 (+1.46)

Horizon Pharma beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 6:12AM CST

HZNP: 20.53 (+1.46)

Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 4:30PM CST

GLOG: 19.79 (+0.63), DFRG: 20.09 (+0.98), AAON: 22.51 (-1.06), DCIX: 2.49 (-0.01), TTI: 5.97 (+0.99), SJI: 56.68 (+0.43), CNCE: 14.39 (-1.26), XLS: 24.20 (-0.08), PNM: 28.55 (+0.23), NWN: 47.25 (-0.20), GDP: 4.48 (+0.24), HTH: 18.60 (-0.93), CAS: 3.22 (-1.81), HZNP: 20.53 (+1.46), PTCT: 71.33 (-2.13), WMC: 15.00 (+0.62), GVA: 33.12 (-1.84), CST: 41.63 (-2.38), LBY: 38.03 (+1.73), HPT: 30.81 (-0.21), KERX: 12.16 (+0.23), POM: 27.14 (-0.02), ISIS: 68.56 (+1.23), CVT: 28.95 (-0.35), HMSY: 17.54 (-1.30), NYLD: 51.31 (-1.83), RDC: 21.61 (+0.92), NRG: 23.98 (-0.79), NRF: 19.22 (-0.24)

Market Is Not In A Bubble - Cramer's Mad Money (2/23/15)
SA Editor Mohit Manghnani - Seeking Alpha - Tue Feb 24, 6:40AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, February 23. With Nasdaq near all-time highs after 15 years, Cramer is listening to people talk about a new bubble forming. He said one of the good things about...
TSLA: 203.34 (-3.85), VRX: 197.48 (-3.77), CYBR: 59.27 (-3.19), AMGN: 157.72 (-1.25), INTC: 33.25 (-0.40), GOOG: 558.40 (+2.92), ORCL: 43.82 (-0.07), CELG: 121.53 (-1.82), AGEN: 4.90 (-0.14), T: 34.56 (+0.06), CTB: 38.06 (-1.11), JPM: 61.28 (-0.30), GILD: 103.53 (-0.66), HZNP: 20.53 (+1.46), GM: 37.31 (-0.25), GOOGL: 562.63 (+3.34), MSFT: 43.85 (-0.21), VZ: 49.45 (+0.08), DOW: 49.24 (-0.01), AAPL: 128.46 (-1.95), REGN: 413.84 (-6.03), CSCO: 29.51 (-0.40)

Why Horizon Pharma PLC Stock Skyrocketed Today
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 20, 1:27PM CST
Although we don't believe in   timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Less than a week after presenting at a...
AZN: 68.90 (-0.11), HZNP: 20.53 (+1.46)

Market Turns Positive As Stocks Stage Reversal
at Investor's Business Daily - Fri Feb 20, 12:32PM CST
Major averages turned positive in early afternoon trading as leading medical stocks continued to dominate. The Dow Jones industrial average led with an 0.3% gain, while the Nasdaq picked up 0.2% and the S&P 500 0.1%. Volume was tracking higher across...
VRX: 197.48 (-3.77), GRUB: 42.01 (+0.26), SLXP: 157.20 (+0.25), HZNP: 20.53 (+1.46)

Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 0.94 (unch), AMRN: 1.51 (+0.05), HWAY: 22.38 (-0.37), HLS: 43.46 (-0.62), CYBX: 68.50 (+1.90), ESRX: 84.79 (+0.25), ECYT: 5.80 (-0.11), DXCM: 60.74 (-1.22), NSTG: 10.51 (-0.08), SRPT: 13.90 (+0.08), HZNP: 20.53 (+1.46), MDXG: 10.35 (-0.13), DEPO: 21.95 (-0.65), ANIK: 39.92 (-0.04), NKTR: 13.07 (+0.09), KERX: 12.16 (+0.23), ALIM: 5.23 (-0.05), EPZM: 23.52 (-0.08), AEGR: 27.20 (+0.20), MDRX: 12.01 (-0.74), ELGX: 15.77 (+0.09), NUVA: 45.75 (+0.76), HPTX: 29.55 (+1.82), GNMK: 12.71 (-0.19), MDVN: 117.53 (-2.21), HBIO: 5.46 (-0.09), ACAD: 37.97 (+0.19), ST: 53.74 (+0.09), RPTP: 9.27 (-0.37), FMI: 47.76 (-0.58), GMED: 24.28 (-0.78), JAZZ: 170.09 (-5.10), PTCT: 71.33 (-2.13), INFI: 15.20 (-0.84), ARNA: 4.51 (-0.24), EXEL: 2.93 (unch), NEO: 4.54 (+0.13), EXAS: 22.47 (-0.89), ALKS: 70.25 (-0.98), HTWR: 85.23 (-1.15), MNKD: 6.52 (-0.30), IPXL: 40.29 (-0.41), SQNM: 3.50 (-0.02), HALO: 15.07 (-0.21), ISIS: 68.56 (+1.23), CLVS: 76.46 (-1.43), BIO: 127.18 (+8.18), BIOS: 6.11 (+0.19), PCRX: 114.77 (-1.22)

Will ARIAD (ARIA) Impress on Iclusig Sales this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 9:40AM CST
ARIAD Pharmaceuticals (ARIA) is set to report fourth-quarter 2014 results on Feb 19.
IPXL: 40.29 (-0.41), ISIS: 68.56 (+1.23), HZNP: 20.53 (+1.46), ARIA: 8.13 (-0.04)

Horizon Pharma expands US headquarters with new Chicago office
M2 - Wed Feb 18, 6:29AM CST
Biopharmaceutical company Horizon Pharma (NASDAQ:HZNP) reported on Tuesday the inauguration of its new office at Chicago, adding more than 25 jobs in the city.
HZNP: 20.53 (+1.46)

Horizon Pharma plc Expands U.S. Headquarters With Opening of Chicago Office
Marketwired - Tue Feb 17, 7:03AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced it has opened a Chicago office.
HZNP: 20.53 (+1.46)

Horizon Pharma submits IND for go-ahead to start FA Phase 3
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 8:15AM CST

HZNP: 20.53 (+1.46)

Technical Notes Covering Pharma Equities -- Valeant Pharma Intl., Salix Pharma, Medicines, Hospira, and Horizon Pharma
PR Newswire - Fri Feb 13, 7:45AM CST
Editor Note: For more information about this release, please scroll to bottom.
VRX: 197.48 (-3.77), MDCO: 28.76 (-0.76), HZNP: 20.53 (+1.46), SLXP: 157.20 (+0.25), HSP: 87.54 (unch), VRX.TO: 246.27 (-5.75)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Grupo Simec 2026 Nine-Month Financial Surge Spells Change

Updated Category News Views 64

Sharp Climb in Net Income Sparks Interest Buckle up, folks. Grupo Simec's nine-month results for 2026 are a mixed bag of surprises and steady flows. Let’s break it down: the net income skyrocketed by a whopping 428% compared to the same period last year—jumping from Ps. 763 million to Ps. 4,028 million. That's a solid leap, and it’s largely due to turning a hefty...

Continue Reading
Cloopen Group's Private Transition: What Investors Should Know

Updated Category News Views 121

Cloopen Steps Away from Public Market Scene Here's a tale simmering on the corporate backburner: Cloopen Group Holding Limited, that cloud juggernaut over in China, has gone all private on us. The ink is drying on their merger with SummerX Holdings Limited, under the overarching umbrella of SpringX Holdings. So, now this communications outfit has slipped out of the public...

Continue Reading
LanguageLine AI App Earns Vizient Technology Kudos

Updated Category News Views 0

Tech Talk: LanguageLine's AI App Gains Important Recognition Diving headfirst into the chaotic world of healthcare, LanguageLine's AI Translation App earned a standout accolade. Just announced, it's snagged the Innovative Technology Designation from Vizient, the heavyweight champ in healthcare performance improvement. On the scene since the end of October, they rolled the...

Continue Reading
Core Lab's Quarterly Grit: Navigating a Turbulent Market

Updated Category News Views 71

Core Lab's Quarter in Review With the kind of resilience that makes a trader's hands shake ever so slightly less over a coffee, Core Laboratories Inc. heads into the fourth quarter of 2026. This isn't your typical Wall Street story, that's for sure. Watching a solid player like Core navigate the bumpy roads of today's volatile market reminds me of a...

Continue Reading
Freddy’s Joins Hershey For a Limited-Time Flavor Fest

Updated Category News Views 95

The Sweet Collaboration We Didn't See Coming Well, folks, here's a tasty twist for you—Freddy's Frozen Custard & Steakburgers is cozying up to The Hershey Company to bring a sugar rush to our mundane lives. Starting Nov. 4, they're rolling out a limited-time series of treats so indulgent you'll want to skip straight to dessert. And if that wasn't enough, they're...

Continue Reading
Bloomberg Law Integrates Docket Data with AI Platform

Updated Category News Views 0

Bloomberg Law's Game-Changer for Legal Pros Here's something that'll make legal eagles perk up on this fine day: Bloomberg Law has rolled out a connector for Claude, marrying court dockets and litigation smarts to AI. Let's face it, the legal world always runs on precision and timing above all. So when an integration like this drops, it ain’t just a memo on the office...

Continue Reading
AppLovin Faces Class Action: AI Growth Claims Under Fire

Updated Category News Views 67

AppLovin's AI Jackpot: A Busted Flush? This year's been a rollercoaster at AppLovin Corporation, and not the fun kind. Let me tell ya, investors bought into a dream—a self-sustaining, profit-churning machine based on AI advertising models. Unfortunately, reality came around like a bad penny, and suddenly, their 'virtuous cycle' feels more like a busted flush....

Continue Reading
Genedata's New ELN Transforms Biopharma R&D Workflows

Updated Category News Views 58

Revolutionizing Research with a New Digital Tool Genedata, the brain behind enterprise software for drug discovery, has thrown a curveball into the world of biopharmaceutical research by launching a pioneering electronic lab notebook (ELN). This isn’t just another software update; it's a complete shift in how R&D workflows are structured and maintained. With an...

Continue Reading
J.H. Strain & Sons' Asset Sale Seals a New Era

Updated Category News Views 59

Texan Legacy Bows Out of the Asphalt Game Here's a fresh chapter in the world of road construction that'll have folks in the industry doing a double-take. Elder Bray & Bankler, a bigwig among corporate law circles, has been guiding this tale. They've shepherded J.H. Strain & Sons through selling off its asphalt manufacturing and construction assets to none other than...

Continue Reading
Motiva's Q3 2026 Results: Strategic Moves Drive Growth

Updated Category News Views 0

Strategic Transactions and Financial Highlights Motiva's third quarter of 2026 shows a company not just coasting but recalibrating its trajectory. Big moves had ripple effects on their financial landscape, most notably their sale of the Airport Platform, concluded for a hefty R$5.2 billion. Their portfolio's trimming isn't just a garage sale but a thought-out step...

Continue Reading

Top 5 Most Recently Viewed Articles

Experience the Magic of Holidays in Wimberley, Texas

Updated Category News Views 214

Wimberley: A Magical Destination This Holiday Season The holiday season brings an enchanting atmosphere filled with sparkling lights, beloved traditions, and joyful celebrations for families. Imagine a place where every day feels like Christmas morning, creating memories that last a lifetime. Hometown Holidays: A Celebration of Joy This year, Wimberley, located in the...

Continue Reading
DIAGNOS Announces Extension of Stock Warrants for Investors

Updated Category News Views 113

DIAGNOS Extends Stock Warrants for Investors Quebec-based Diagnos Inc. (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), known for its innovative technology in early detection of health issues, recently announced an extension for the exercise period of certain stock warrants. This extension covers an aggregate of 650,000 stock warrants issued during a non-brokered private...

Continue Reading
DICK'S Sporting Goods Initiates Exchange Offer for Foot Locker Debt

Updated Category News Views 198

DICK'S Sporting Goods Launches Debt Exchange Offer DICK'S Sporting Goods, Inc. (NYSE: DKS), a prominent U.S. full-line omni-channel sporting goods retailer, has officially announced a strategic move to enhance its financial leverage through the initiation of an exchange offer. This move comes as part of their anticipated acquisition of Foot Locker, Inc. Understanding the...

Continue Reading
Investors of Customers Bancorp Can Pursue Class Action Claims

Updated Category News Views 175

Class Action Lawsuit Filed for Customers Bancorp Investors In recent developments, Glancy Prongay & Murray LLP, a significant player in shareholder rights law, has announced the filing of a class action lawsuit aimed at protecting investors of Customers Bancorp, Inc. This lawsuit is particularly relevant for those who purchased shares between March 1, 2024, and August 8,...

Continue Reading
Shenzhen's Innovative Blue Carbon Model Shines at UN Conference

Updated Category News Views 184

Shenzhen's Blue Carbon Initiative at Global Stages At the recent UN Climate Change Conference, Shenzhen grabbed attention as a leader in blue carbon initiatives. The conference provided a vibrant platform for dialogue on the role of mangroves in climate governance and sustainable development. The event, titled "Blue Carbon for a Greener Future, Mangroves for Shared...

Continue Reading